The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).
 
Jacob E Berchuck
No Relationships to Disclose
 
Rebecca Silver
No Relationships to Disclose
 
Ziad Bakouny
No Relationships to Disclose
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Anis Hamid
Honoraria - Bayer
Consulting or Advisory Role - MSD
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Matthew L. Freedman
No Relationships to Disclose
 
Mark Pomerantz
Honoraria - Bayer
 
Mary-Ellen Taplin
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Merck; Pfizer; Progenics; Research to Practice; UpToDate
Consulting or Advisory Role - AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals